期刊
BRITISH JOURNAL OF HAEMATOLOGY
卷 154, 期 4, 页码 477-481出版社
WILEY
DOI: 10.1111/j.1365-2141.2011.08781.x
关键词
lenalidomide; transformed lymphoma; transformed chronic lymphocytic leukaemia; transformed follicular lymphoma; transformed small lymphocytic lymphoma
类别
资金
- Celgene Corporation
- Celgene
Transformed lymphoma (TL) represents a heterogeneous group of lymphomas with an aggressive course and poor prognosis. We assessed the clinical benefit of single-agent lenalidomide based on histological origin, including transformed follicular lymphoma (tFL) and transformed chronic lymphocytic leukaemia/small lymphocytic lymphoma (tCLL/SLL). Our analysis included 33 patients with TL. Patients received lenalidomide at a median dose of 25 mg/d. The overall response rate (ORR) was 46%, with a median response duration of 12 8 months after a median follow-up of 5 6 months. Median progression-free survival was 5 4 months. Among patients with tFL, ORR was 57%, with a median response duration of 12 8 months. None of the patients with tCLL/SLL responded to lenalidomide monotherapy. The most common grade 3/4 adverse events were reversible myelosuppression. Our results suggest that the original lymphoma histology (i.e. FL) in TL patients may potentially be associated with response to salvage lenalidomide monotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据